ConductScience.org, home

Comparison · NCT04852679-deaths

Main Intervention Period: Lanreotide Autogel 120 mg vs Independent Injection Period: Lanreotide Autogel 120 mg: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Main Intervention Period: Lanreotide Autogel 120 mg vs Independent Injection Period: Lanreotide Autogel 120 mg: deaths from any cause. Trial comparisons, record NCT04852679-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04852679-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04650.01280.155wilson
Risk in group 2000.434wilson
Risk difference, group 1 minus group 20.0465-0.3890.155newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more death from any cause on Main Intervention Period: Lanreotide Autogel 120 mg than on Independent Injection Period: Lanreotide Autogel 120 mg21.5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Main Intervention Period: Lanreotide Autogel 120 mgAll participants received a fixed dose of lanreotide autogel 120 mg SC injection every 28 days up to 48 weeks.243EG000
Group 2Independent Injection Period: Lanreotide Autogel 120 mgEligible participants received a fixed dose of lanreotide autogel 120 mg SC injection every 28 days for 24 weeks.05EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Main intervention period: Treatment-emergent adverse events (TEAEs) were reported from first injection of study intervention up to Week 48, approximately 48 weeks. Independent injection period: TEAEs were reported from Week 48 to end of study or 4 weeks after last injection of study intervention, approximately 28 weeks.

Source ClinicalTrials.gov

Trial

Title
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
NCT number
NCT04852679
Phases
PHASE3
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Lanreotide autogel
Lead sponsor
Ipsen
Results first posted
2024-10-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04852679-deaths